Document is current
Any future updates will be listed below
-
Authors
Wang, Sung Eun https://orcid.org/0000-0002-0526-588X
Cheng, Yubao https://orcid.org/0000-0001-6967-1433
Lim, Jaechul
Jang, Mi-Ae https://orcid.org/0000-0002-6558-5236
Forrest, Emily N.
Kim, Yuna
Donahue, Meaghan
Jo, Sungsin
Qiao, Sheng-Nan
Lee, Dong Eun
Hong, Jun Young
Xiong, Yan https://orcid.org/0000-0002-3862-3663
Jin, Jian https://orcid.org/0000-0002-2387-3862
Wang, Siyuan https://orcid.org/0000-0001-6550-4064
Jiang, Yong-hui https://orcid.org/0000-0001-6188-8806
- License Information
-
More Information
Article History
Received: 20 June 2024
Accepted: 13 June 2025
First Online: 3 July 2025
Competing interests
: Y-H.J. is a co-founder of, have an equity interest in, a scientific advisor to, and have an unpaid seat on the board of directors to Couragene, Inc., a biotechnology company that has licensed his intellectual property. However, Couragene did not have any direct role in this paper. J.J., Y.X., Y-H.J., and S.E.W. are described in a patent application for MS1262 as inventors, titled “G9A/GLP INHIBITORS AND METHODS OF USE” which was filed in the United States Patent and Trademark Office as application 63/515,010 (the “Application”). S.W. is an inventor on patent applications related to the chromatin tracing technology applied for by Harvard University and Yale University. The remaining authors declare no competing interests.
